Our MacCAT instrument comprises a suite of computerised adaptive tests (CATs) that measure the impact of AMD (Age-related macular degeneration) and associated vision loss on 7 domains of quality of life.

With a user-friendly interface and automated feedback system, MacCAT offers researchers, clinicians and clinical trial teams a precise and efficient PROM to evaluate the effectiveness of treatments and interventions, including laser therapy and intravitreal injections, from the patient’s perspective.

It is currently under development and is anticipated to be available in 2023.